IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1026-1050 out of 1286.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

Public Release: 3-Mar-2014
Journal of Clinical Oncology
Yoga regulates stress hormones and improves quality of life for women with breast cancer undergoing radiation therapy
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to research from The University of Texas MD Anderson Cancer Center.

Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center

Public Release: 3-Mar-2014
PLOS ONE
BPA linked to prostate cancer, study shows
Findings by Cincinnati Cancer Center researchers show that levels of bisphenol A (BPA) in men's urine could be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both non-malignant and malignant prostate cells.
National Institutes of Health, Department of Defense, University of Cincinnati

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 3-Mar-2014
Journal of Experimental Medicine
Gut microbes spur development of bowel cancer
It is not only genetics that predispose to bowel cancer; microbes living in the gut help drive the development of intestinal tumors, according to new research in mice.
National Institutes of Health

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 3-Mar-2014
Proceedings of the National Academy of Sciences
Big stride in understanding PP1, the ubiquitous enzyme
The enzyme PP1 has a key role in many of the body's healthy functions and diseases. It's so generally important that drug developers dare not target it. In a new study in the Proceedings of the National Academy of Sciences, Brown University scientists report a big leap in understanding how PP1 interacts with other proteins to behave specifically in distinct situations. That could lead to medicines that target it for precise benefits.
NIH/National Institute of General Medical Sciences

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University

Public Release: 1-Mar-2014
Oncotarget
Improved screening means new targets for pediatric neuroblastoma therapies
Neuroblastoma is one of the most common and lethal types of childhood cancers. In a paper published online today in OncoTarget, a researcher at the University of Texas Health Science Center at San Antonio unveils an improved screening technique that shows the important role of microRNAs in regulating neuroblastoma development, pointing to new therapeutic possibilities.

Contact: Elizabeth Allen
allenea@uthscsa.edu
210-450-2020
University of Texas Health Science Center at San Antonio

Public Release: 28-Feb-2014
New England Journal of Medicine
BNI study reveal unexpected findings
Research on a deadly form of brain cancer co-authored by a physician at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The three-year research project led locally by David Brachman, M.D., revealed that a 'promising' drug therapy failed to improve survival among patients with newly diagnosed glioblastoma.
NIH/National Cancer Institute

Contact: Lynne Reaves
lynne.reaves@dignityhealth.org
602-406-4734
St. Joseph's Hospital and Medical Center

Public Release: 28-Feb-2014
FASEB Journal
Tackling tumors with space station research
Some tumors seem to be much less aggressive in space compared to their behavior on Earth, which could help scientists understand the mechanism involved and develop drugs targeting tumors that don't respond to current treatments.
German Space Agency

Contact: Laura Niles
Laura.E.Niles@nasa.gov
281-244-7069
NASA/Johnson Space Center

Public Release: 28-Feb-2014
American Journal of Transplantation
American Journal of Transplantation reports REGiMMUNE's transplant tolerance results
REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term tolerance in organ transplantation with continuous administration of immune suppressants. "A Novel Approach Inducing Transplant Tolerance by Activated Invariant Natural Killer T Cells with Costimulatory Blockade" was published in the AJT March 2014 Issue 3, Volume 14, pages 554-567, and was first made available online as an early view on Feb. 6, 2014.

Contact: Debra Bannister
debracb77@gmail.com
530-676-7373
REGiMMUNE

Public Release: 28-Feb-2014
European Urology
UCLA study finds robotic-assisted prostate surgery offers better cancer control
Robotic-assisted surgery for prostate cancer has fewer positive surgical margins than open surgery. Patients who had robotic surgery needed fewer additional cancer treatments afterward. Higher upfront robotic costs may be offset by a reduction of additional cancer therapy costs after surgery due to better cancer control outcomes.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 28-Feb-2014
Small
Let there be tissue-penetrating light: Scientists develop new nanoscale method to fight cancer
Researchers from the cancer nanotechnology and signal transduction and therapeutics programs of UCLA's Jonsson Comprehensive Cancer Center have developed an innovative technique that can carry chemotherapy safely and release it inside cancer cells when triggered by two-photon laser in the infrared red wave length.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 28-Feb-2014
New England Journal of Medicine
Long-term study confirms success of method for detecting spread of deadly skin cancer
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 27-Feb-2014
Developmental Cell
Discoveries point to more powerful cancer treatments, fewer side effects
A Rutgers study suggests a way to make chemotherapy and radiation more effective as cancer treatments while eliminating debilitating side effects. The approach eliminates eEF2K -- an enzyme that influences the rates at which proteins are created in the human body. The enzyme's presence tends to leave cells less robust than they otherwise would be, and that added weakness leaves healthy cells vulnerable to being poisoned by chemo and radiation.

Contact: Rob Forman
robert.forman@rutgers.edu
973-972-7276
Rutgers University

Public Release: 27-Feb-2014
Journal of Biological Chemistry
Scientists discover new protein involved in lung cancer
The research by the Manchester team looked at glucocorticoids, the hormones that regulate inflammation and energy production in cells in the body. In lung cancer these hormones are known to play a role in controlling cell growth. Glucocorticoids work through receptors, and this new research reveals how these receptors work.

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 27-Feb-2014
Science Translational Medicine
CNIO researchers discover new strategies for the treatment of psoriasis
Almost 10 years ago, the group led by Erwin Wagner developed genetically modified mice showing symptoms very reminiscent to psoriasis. After publishing this discovery in Nature, the researchers decided to use this mouse model to study the underlying molecular pathways involved in disease development, and to look for innovative and efficient therapies. Now the group has discovered two possible novel treatments, based on existing pharmacological compounds, which are likely to cause fewer side effects.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 27-Feb-2014
A world free from cancers: Probable, possible, or preposterous?
A panel of leading health, economics and policy experts today discussed the prospects for a future where cancers are rendered manageable or even eradicated and the variables affecting progress toward that goal so that cancer patients are able to lead normal, productive lives -- and thus be 'free from' their cancers. The forum was hosted by Research!America and the Pancreatic Cancer Action Network. The event, titled, 'A World Free from Cancers: Probable, Possible, or Preposterous?' was held at the New York Academy of Sciences.

Contact: Suzanne Ffolkes
sffolkes@researchamerica.org
571-482-2710
Research!America

Public Release: 27-Feb-2014
Gene Therapy
Cancer vaccine could use immune system to fight tumors
Cincinnati Cancer Center and University of Cincinnati Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune system, could initiate the immune response to fight cancer.
NIH/National Cancer Institute, LCS Foundation Cincinnati, University of CincinnatiNIH/National Cancer Institute, LCS Foundation Cincinnati, University of Cincinnati

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center

Public Release: 27-Feb-2014
Oncogene
Targeting metabolism to develop new prostate cancer treatments
A University of Houston scientist is working to develop the next generation of prostate cancer therapies targeted at metabolism. Daniel Frigo is looking at a cascade of biochemical reactions inside the cell, focusing on an enzyme considered a master regulator of metabolism. Frigo wants to unlock more effective and less harmful treatments. Funded by the Department of Defense and National Institutes of Health, he most recently received another grant last week from Golfers Against Cancer.
Golfers Against Cancer, US Department of Defense, National Institutes of Health, and others

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston

Public Release: 27-Feb-2014
Science
Researchers discover unusual genetic mutation linked to adolescent liver cancer
In the race for better treatments and possible cures, rare diseases are often left behind. In a collaboration of researchers at The Rockefeller University, Memorial Sloan Kettering Cancer Center and the New York Genome Center, an unusual mutation has been found that is strongly linked to one such disease: a rare liver cancer that affects teens and young adults.
Fibrolamellar Cancer Foundation

Contact: Zach Veilleux
zveilleux@rockefeller.edu
212-327-8982
Rockefeller University

Public Release: 27-Feb-2014
Reproductive Toxicology
Bisphenol A (BPA) at very low levels can adversely affect developing organs in primates
Bisphenol A is a chemical that is used in a wide variety of consumer products and exhibits hormone-like properties. Fetuses, infants, children or adults exposed to the chemical have been shown to exhibit numerous abnormalities, including cancer, as well as reproductive, immune and brain-behavior problems. Now, researchers at the University of Missouri have determined that daily exposure to very low concentrations of bisphenol A by pregnant females also can cause fetal abnormalities in primates.
NIH/National Institute of Environmental Health Sciences

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia

Public Release: 27-Feb-2014
Cancer Research
Study identifies possible new target for future brain cancer drugs
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat glioblastoma, the most frequent and lethal form of brain cancer. The findings suggest that the protein PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease.
NIH/National Institute of Neurological Disorders and Stroke, Ohio Cancer Research Associates, V Foundation

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center

Public Release: 27-Feb-2014
Cell
Study reveals mechanisms cancer cells use to establish metastatic brain tumors
New research from Memorial Sloan Kettering provides fresh insight into the biologic mechanisms that individual cancer cells use to metastasize to the brain.
National Institutes of Health, US Department of Defense Innovator Award, Alan and Sandra Gerry Metastasis Research Initiative

Contact: Caitlin Hool
hoolc@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center

Public Release: 27-Feb-2014
Lancet
Nobelist James Watson proposes an unconventional view of type 2 diabetes causation
At 85, Nobel laureate James D. Watson, the co-discoverer of the double-helix structure of DNA, continues to advance intriguing scientific ideas. His latest, a hypothesis on the causation of type 2 diabetes, is to appear 7 p.m. Thursday US time in the online pages of The Lancet, the prestigious British medical journal.

Contact: Peter Tarr
tarr@cshl.edu
516-367-5055
Cold Spring Harbor Laboratory

Public Release: 26-Feb-2014
Clinical Gastroenterology and Hepatology
Screen some patients with acute pancreatitis for pancreatic cancer, SLU researchers suggest
Banke Agarwal, M.D., associate professor of gastroenterology and hepatology at Saint Louis University, says there is a much higher risk of pancreatic cancer in patients with acute pancreatitis than commonly believed.

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University

Public Release: 26-Feb-2014
Journal of Experimental Medicine
Experimental treatment developed at UCLA eradicates acute leukemia in mice
A team of scientists from the University of California Los Angeles Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles

Public Release: 26-Feb-2014
Molecular Cell
Fox Chase researchers discover new mechanism of gene regulation
Additional insights into how cancer cells use PARP1 enzyme to resist current therapies may also point to the next generation of cancer drugs.
National Institutes of Health

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center

Showing releases 1026-1050 out of 1286.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

  Search News Releases

     

 

 

EurekAlert!